| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.05.
| Ligand Pharmaceuticals Has Returned 25.2% Since SmarTrend Recommendation | | 2 | SmarTrend |
| 23.05.
| Relatively Low Earnings Yield Detected in Shares of Ligand Pharmaceuticals in the Biotechnology Industry | | - | SmarTrend |
| 16.05.
| LIGAND PHARMACEUTICALS INC - 10-K/A, Annual Report | | - | SEC Filings |
| 16.05.
| Ligand Pharmaceuticals Down 21.1% Since SmarTrend Downtrend Call | | - | SmarTrend |
| 15.05.
| Ligand Pharmaceuticals is Among the Companies in the Biotechnology Industry With the Highest Future Earnings Growth | | 1 | SmarTrend |
| 14.05.
| CORRECTING and REPLACING Ligand to Present at the Jefferies 2012 Global Healthcare Conference on June 4 | | 33 | Business Wire |
| Conference in headline and first graph, first sentence of release should
read: Jefferies 2012 Global Healthcare Conference (sted 2011).
The corrected release...
Mehr lesen zu:
CORRECTING and REPLACING Ligand to Present at the Jefferies 2012 Global Healthcare Conference on June 4 | |
| 14.05.
| Ligand to Present at the Jefferies 2011 Global Healthcare Conference on June 4 | | 30 | Business Wire |
| Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced
today that John Higgins, President and Chief Executive Officer, and Matt
Foehr, Executive Vice President and...
Mehr lesen zu:
Ligand to Present at the Jefferies 2011 Global Healthcare Conference on June 4 | |
| 07.05.
| Ligand to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on May 17 | | 53 | Business Wire |
| Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced
today that John Higgins, President and Chief Executive Officer will
present at the Bank of America Merrill...
Mehr lesen zu:
Ligand to Present at the Bank of America Merrill Lynch 2012 Health Care Conference on May 17 | |
| 04.05.
| LIGAND PHARMACEUTICALS INC - 10-Q, Quarterly Report | | - | SEC Filings |
| 02.05.
| Ligand Pharmaceuticals Reports First Quarter Results | | 31 | Business Wire |
| Webcast with Slides and Conference call begin at 4:30 p.m. Eastern
time today
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported
...
Mehr lesen zu:
Ligand Pharmaceuticals Reports First Quarter Results | |
| 02.05.
| Trevena Enters Research Collaboration with Merck To Identify Novel Biased Ligand Molecules | | 30 | Business Wire |
| Trevena, Inc., the leader in the discovery and development of G-protein
coupled receptor (GPCR) biased ligands, today announced the initiation
of a research collaboration...
Mehr lesen zu:
Trevena Enters Research Collaboration with Merck To Identify Novel Biased Ligand Molecules | |
| 16.04.
| Ligand to Report First Quarter Results on May 2nd | | 37 | Business Wire |
| Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced
today plans to report first quarter 2012 financial results on Wednesday,
May 2, 2012. Ligand's President and...
Mehr lesen zu:
Ligand to Report First Quarter Results on May 2nd | |
| 04.04.
| Ligand Pharmaceuticals Has Returned 27.6% Since SmarTrend Recommendation | | 1 | SmarTrend |
| 05.03.
| Ligand to Present at the 24th Annual Roth Conference on March 12 | | 41 | Business Wire |
| Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced
today that John Higgins, President and Chief Executive Officer and Matt
Foehr, Chief Operating Officer and...
Mehr lesen zu:
Ligand to Present at the 24th Annual Roth Conference on March 12 | |
| 21.02.
| Ligand to Present at the Citi Global Health Care Conference on February 28th | | 43 | Business Wire |
| Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced
today that John Higgins, President and Chief Executive Officer of
Ligand, will present at the Citi Global...
Mehr lesen zu:
Ligand to Present at the Citi Global Health Care Conference on February 28th | |
| 21.02.
| Ligand (LGND) Licenses DARA to Retrophin; May Get Up to $75M in Milestone Payments | | 2 | StreetInsider.com |
| 21.02.
| Ligand Licenses DARA Program to Retrophin | | 36 | Business Wire |
| Potential for over $75 million in milestone payments to Ligand plus
royalties
Retrophin plans to develop DARA for rare nephropathies and other
indications
Ligand...
Mehr lesen zu:
Ligand Licenses DARA Program to Retrophin | |
| 13.02.
| Trevena Initiates Clinical Development of TRV130, a Biased Mu-Opioid Ligand for Severe Post-Operative Pain | | 28 | Business Wire |
| Biased ligand offers powerful analgesia with reduced opioid side
effects
Trevena, Inc., the leader in discovery and development of G-protein
...
Mehr lesen zu:
Trevena Initiates Clinical Development of TRV130, a Biased Mu-Opioid Ligand for Severe Post-Operative Pain | |
| 10.02.
| LIGAND PHARMACEUTICALS INC - 10-Q/A, Quarterly Report | | 5 | SEC Filings |
| 09.02.
| Ligand to Present at the BIO CEO and Investor Conference on February 13 | | 53 | Business Wire |
| Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced
today that John Higgins, President and Chief Executive Officer of Ligand
will present at the BIO CEO and Investor...
Mehr lesen zu:
Ligand to Present at the BIO CEO and Investor Conference on February 13 | |
